Drugs & Targets FDA grants Fast Track designation to Syncromune Inc. for drug-device combo for solid tumors in mCRPC July 05, 2024Vol.50 No.27
Drugs & Targets EMA CHMP adopts positive opinion for Tepkinly in R/R follicular lymphoma July 05, 2024Vol.50 No.27
Drugs & Targets EMA CHMP adopts positive opinion for odronextamab for R/R follicular lymphoma or R/R DLBCL July 05, 2024Vol.50 No.27
Drugs & Targets eHealth Technologies, CancerX collaborate to accelerate cancer innovation in U.S. June 28, 2024Vol.50 No.26
Drugs & Targets Merck, Qure.ai collaborate to expand lung cancer detection via AI June 28, 2024Vol.50 No.26
Drugs & Targets FDA approves Keytruda combination for primary advanced or recurrent endometrial carcinoma June 21, 2024Vol.50 No.25
Drugs & Targets EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines June 21, 2024Vol.50 No.25
Drugs & Targets FDA clears IND application for ZW171, a 2+1 T-cell targeting bispecific antibody for mesothelin-expressing cancers June 21, 2024Vol.50 No.25
